- Baked In
- Posts
- đź’¸ Growth Is On The Horizon đź’¸
đź’¸ Growth Is On The Horizon đź’¸
William McNarland & Anthony Varrell
May 29, 2024
GM Everyone,
The adult-use movement across the nation is something that should not be overlooked. Markets such as New Hampshire, Delaware, Ohio, Pennsylvania, Virginia, and Florida are all progressing toward an adult-use market. While some are much closer than others, the fact that we can compile a significant list indicates that progress and future growth are happening all around us. Some of these markets will come online in 2024, and others will be a 2025 story (come on, FL). Either way, the Total Addressable Market (TAM) is growing daily, and the growth narrative is closer than ever to fully coming back into the equation.
Today’s letter can be read in 5 minutes and 42 seconds.
What's Driving the Market Today?
Futures are down this morning, here is what is moving the market:
Bond yields and VIX hit 4-week highs on U.S. consumer resilience.
$297B Treasury auction met with weak demand, pushing yields up.
Nvidia's 6% surge boosts Nasdaq to record highs, near 17,000.
Sticky inflation globally, with Australia at a 5-month high.
Oil sector mergers: ConocoPhillips eyes Marathon Oil, Hess-Chevron deal approved.
TDR Research Initiating Coverage of Trulieve Cannabis
Quick Hit: Trulieve exhibits several strengths that enhance its attractiveness as an investment. The company demonstrates robust cost management and profitability, as reflected in its higher-than-average gross profit margin. Additionally, Trulieve has shown strong cash flow management, with a high Levered Free Cash Flow (LFCF) Margin and significant positive change over the last twelve months. These factors contribute to Trulieve’s financial flexibility and ability to invest in growth opportunities, pay dividends, and weather economic downturns.
InMed Pharmaceuticals Leads Alzheimer Research Breakthroughs
Facts that matter:
InMed Pharmaceuticals focuses on cannabinoids for Alzheimer’s treatment.
InMed’s Alzheimer compounds target multiple brain pathways.
InMed’s Alzheimer research gains expert endorsement
Quick Hit: InMed Pharmaceuticals (NASDAQ- INM), is at the forefront of research in Alzheimer’s treatment. With an innovative approach that leverages cannabinoid analogs and small molecule drug candidates. Alzheimer’s disease affects millions worldwide, leading to severe cognitive decline, memory loss, and anxiety. Despite extensive research and investment, current treatments offer limited efficacy. Traditional approaches, such as targeting amyloid beta plaques, have shown modest success at best. Eric Adams, CEO of InMed Pharmaceuticals, highlights the shortcomings of these approaches: “What they learned, though, is once you reduce the amount of the plaque, you don’t necessarily see an improvement. You can maybe delay the disease to some degree, but you can’t stop it and you can’t reverse the effects of what’s already happened.”
Coverage Initiated: New Lake Capital Partners
NewLake Capital stands out in the small-cap stock market for its strong financials and its unique position in the cannabis sector. The company’s business model operates on a simple yet efficient premise where it serves as a landlord to cannabis operations, offering real estate solutions that are both strategic and lucrative.They take in the money from the cannabis companies and manage it. The company takes a narrow, thin charge for doing that.
CWENCH Hydration: Cizzle Brands’ New Sports Drink Endorsed by Top Athletes
Facts that matter:
Athletes Nathan MacKinnon, Andrew Wiggins, and Adriana Leon endorse CWENCH Hydration.
Strength coach Andy O’Brien highlights CWENCH Hydration’s scientific formulation.
CWENCH Hydration set to launch in major Canadian retailers.
Quick Hit: John Celenza, Cizzle Brands’ Founder and CEO, said “CWENCH Hydration is the result of extensive collaboration amongst world-class athletes, elite trainers and our Cizzle Brands team,”. He added in his press release “When we approached Andy to develop CWENCH, we gave him an open canvas to create something that not only truly aids in hydrating your body for better performance, but is also something we feel good giving to our families.”
InMed Pharmaceuticals and Alzheimer’s Research | Trade to Black
Join our Trade to Black Podcast with InMed Pharmaceuticals (NASDAQ: INM) CEO Eric Adams to learn how the company is pioneering Alzheimer’s treatment with innovative cannabinoid analogs. InMed focuses on cannabinoid analogs to treat Alzheimer’s, targeting multiple brain pathways for enhanced efficacy. InMed Pharmaceuticals is at the forefront of Alzheimer’s research, offering hope to millions and presenting a promising investment opportunity.